Exhibit 99.2
FINANCIAL SUMMARY
2002 2003 2004E 2005E 2006E
Revenues $0 $0 $185 $3,375 $15,175
Operating Expenses
Research and development 310 929 1,770 5,992 4,732
General and administrative 400 739 1,039 1,391 1,413
------------------------------------------------------------------------------
710 1,668 2,809 7,383 6,145
Operating income (loss) (710) (1,668) (2,624) (4,008) 9,030
Net income (loss) $(700) $(1,673) $(2,580) $(3,867) $9,204
FY 2004 revenue estimates are based on Small Business Innovation Research (SBIR)
awards granted by the National Institute of Allergy and Infectious Diseases.
Thereafter, revenue projections include follow-on grants, upfront payments upon
execution of licensing agreements, milestone payments and product royalties.
Royalty payments are expected to begin in FY 2006 with initial commercialization
of the oral probiotics in Asia and Europe. Commercialization of the replacement
therapy and Mutacin 1140 is anticipated to begin in FY 2009.
Estimated expenses include significantly higher R&D expenses, additional
salaries for new hires, consulting fees for R&D consultants and advisors,
patent- and licensing-related fees, costs of contract manufacturing, and higher
depreciation and amortization expenses associated with capital expenditures.
Although the Company anticipates in-licensing and developing additional
technologies, no provision is made in these estimates for the cost of such
in-licensing or the generation of revenues that might occur.
CAVEAT: These financial projections are forward looking statements that have
been prepared based upon certain assumptions and hypotheses which management
believes are reasonable and should be read in conjunction with the Company's
historical audited financial statements. These projections are only estimates
and are necessarily speculative in nature. These financial projections have not
been audited or reviewed by independent accountants and may be subject to future
reconciliation and adjustment. The assumptions and estimates underlying these
projections are subject to significant business, economic and competitive
uncertainties beyond the Company's control as well as the risk factors set forth
in the Company's SEC filings. Variations of actual facts and circumstances from
the assumptions could and materially alter the actual future financial results
achieved by the Company. As such, these financail projections may be materially
different from the Company's actual, future results. No assurance can be that
any projections or assumptions will prove to be accurate.